^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Kaitanni (cadonilimab) (PD1 inhibitor, CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Akeso’s Cadonilimab (PD-1/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China
Published date:
06/26/2022
Excerpt:
Akeso, Inc....announced that its PD-1/CTLA-4 bi-specific antibody (Cadonilimab injection, AK104) has received marketing approval from the National Medical Products Administration (NMPA) of China, for the treatment of relapsed or metastatic cervical cancer (R/M CC) patients who progressed on or after platinum-based chemotherapy....The approval by NMPA is based on the positive results across a pivotal Phase II clinical study on Cadonilimab for treatment of R/M CC patients who progressed on or after platinum-based chemotherapy.
Source:
Title:
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients
Published date:
11/27/2023
Excerpt:
Akeso...announced that the AK104-303 Phase III trial, which investigated cadonilimab (Akeso's PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy +/- bevacizumab, has met one of its primary endpoints of progression-free survival (PFS) for first-line treatment of recurrent/metastatic cervical cancer (R/M CC), with p-value of less than 0.0001.
Secondary therapy:
Chemotherapy
